2024-08-19T16:09:54-07:00 2023-12-31 990 2023-01-01 824322538 AIM-HI ACCELERATOR FUND INC AIM- 3016541250 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 Kwok Leung CFO 3019619115 2024-08-08 1 2023 2024-08-08 14:25:15Z AIM HI TRANSLATIONAL RESEARCH INC SUJUAN BA 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 2069894 0 X WWW.AIM-HIACCELERATOR.ORG X 2019 MD AIM-HI Accelerator Fund Inc's mission is to bridge the gap and accelerate new oncology therapies and technologies across the "Valley of Death" through high-impact investment approaches. 7 7 0 50 0 0 3905995 2022246 0 0 0 47648 0 0 3905995 2069894 35500 25000 0 0 0 0 0 0 7357 140185 624482 175685 649482 3730310 1420412 13356814 14774789 7412 4975 13349402 14769814 The AIM-HI Accelerator Fund is an independent 501(C)(3) non-profit organization, established with an initial grant from the National Foundation for Cancer Research with the vision to accelerate the translation of cancer drug discoveries by investing in seed-stage companies. It is a new paradigm through venture philanthropy to fund start-up oncology companies that commercialize innovative laboratory breakthroughs which can potentially save cancer patients' lives. 0 0 632119 25000 0 Leveraging immediately deployable venture philanthropy funding to provide seed funding and sustainable impact investment for oncology start-ups to bridge the "Valley of Death" funding gap and bring innovative new therapies, diagnostics and cancer prevention to patients. 7358 0 Cancer Awareness 0 0 0 639477 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 7 7 1 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 X Kwok Leung 3019619115 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 X MATTHEW TREMBLAY CHAIRMAN OF THE BOARD 2 X 0 0 0 BRIAN LEYLAND-JONES VICE CHAIRMAN OF THE BOARD 1.5 X 0 0 0 FRANKLIN SALISBURY JR CO-FOUNDER AND DIRECTOR 1.5 X 0 0 0 CHARLIE WEATHERSPOON CO-FOUNDER AND DIRECTOR 1.5 X 0 0 0 MARK BARAN DIRECTOR 1 X 0 0 0 ALFRED SLANETZ DIRECTOR 1 X 0 0 0 ROSE WANG served from May 2023 DIRECTOR 1 X 0 0 0 YAJUN XU served up to May 2023 DIRECTOR 1 X 0 0 0 SUJUAN BA CO-FOUNDER AND CEO 12 X 0 0 0 KWOK LEUNG TREASURER/SECRETARY 12 X 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2022246 0 2022246 0 47648 0 0 47648 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2069894 0 0 47648 25000 25000 2560 2560 88 88 14715 7358 0 7357 19307 19307 49812 49812 Program-Related Investment Write-Down 538000 538000 0 649482 639477 2648 7357 X 14715 7358 0 7357 670669 719235 797648 1005250 850000 11680895 12407906 13356814 14774789 7412 4975 7412 4975 X 13349402 2361908 0 12407906 13349402 14769814 13356814 14774789 1420412 0 0 0 0 0 X 0 0 0 X 5812621 3345219 3905995 2022246 15086081 0 5812621 3345219 3905995 2022246 15086081 15086081 14109 4 47648 61761 15147842 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED INTERLEUKIN COMBINATORIAL THERAPEUTICS INC 1210000 C INVAMET THERAPEUTICS INC 1267500 C ONCOHEROES BIOSCIENCES INC 500000 C RASIO THERAPEUTICS 1000000 C SCITECH DEVELOPMENT LLC 310332 C AKROTOME IMAGING INC 267566 C STROMATIS PHARMA 1037500 C PRIVO TECHNOLOGIES 300000 C WINDOW THERAPEUTICS 1300000 C TVARDI THERAPEUTICS 500000 C TELLBIO INC 400000 C CATALIO GENESIS FUND 500000 C SPOROS BIOVENTURES LLC 999998 C YIVIVA INC 600000 C DOT-BIO PTE LTD 350000 C ARBELE INVESTMENT LIMITED 450000 C CHIMERA BIO 999999 C ANGELINK INC 415011 C 12407906 1 GEORGETOWN UNIVERSITY OAUR 37TH AND O STREETS NW WASHINGTON DC 20057 530196603 501(C)(3) 10000 ESTABLISHING ENTREPRENEURIAL FELLOWSHIP PROGRAM AT GEORGETOWN UNIVERSITY. MARCH BIOSCIENCES INC 2450 HOLCOMBE BLVD SUITE X HOUSTON TX 77021 863561504 10000 CANCER RESEARCH COMPETITION AWARD 1 1 Schedule I, Part I, Line 2 Grant recipients are required to submit annual progress reports to our organization. Form 990, Part VI, Section A, Line 2 BOARD DIRECTOR FRANKLIN SALISBURY, JR. AND CEO SUJUAN BA ARE HUSBAND AND WIFE. Form 990, Part VI, Section A, Line 6 THE ORGANIZATION SHALL NOT HAVE CAPITAL STOCK AND SHALL HAVE NO AUTHORITY TO ISSUE CAPITAL STOCK. THE ORGANIZATION'S BOARD OF DIRECTORS SHALL BE ITS MEMBERS. Form 990, Part VI, Section A, Line 7a AS THE INCORPORATOR AND THE INITIAL GRANTER TO THE ORGANIZATION, NATIONAL FOUNDATION FOR CANCER RESEARCH (NFCR) HAS THE POWER TO APPOINT TWO DIRECTORS TO THE BOARD, PROVIDED THAT, AT ALL TIMES, THE PERCENTAGE OF REPRESENTATION OF NFCR SHALL BE LESS THAN 40% OF THE TOTAL NUMBER OF DIRECTORS SERVING ON THE BOARD OF THE ORGANIZATION. Form 990, Part VI, Section B, Line 11b REVIEW PROCESS OF FORM 990: (1) FORM 990 WILL BE PREPARED BY THE TREASURER AFTER THE ANNUAL FINANCIAL STATEMENTS ARE PREPARED; (2) THE FIRST DRAFT WILL BE REVIEWED BY THE CEO; (3) AFTER RESOLVING ANY QUESTIONS AND UPDATES, THE REVISED DRAFT WILL BE SENT TO THE BOARD OF DIRECTORS, PREFERABLY ELECTRONICALLY FOR THEIR RESPECTIVE REVIEW AND COMMENTS; (4) COMMENTS FROM THE BOARD OF DIRECTORS; IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN; (5) THE TAX RETURN WILL BE FILED WITH THE INTERNAL REVENUE SERVICE (IRS) PRIOR THE DESIGNATED DUE DATE OR EXTENDED DUE DATE; (6) IN THE RARE OCCASSION THAT THERE IS INSUFFICIENT TIME PRIOR TO THE DUE DATE TO SHARE THE TAX RETURN WITH THE BOARD, OR THERE IS ABSENCE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW BY THE BOARD PRIOR TO THE FILING DEADLINE, A FILED COPY OF THE TAX RETURN WILL BE AVAILABLE FOR BOARD OF DIRECTORS' REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO THE IRS. AN AMENDED RETURN, IF NECESSARY, WILL BE FILED. Form 990, Part VI, Section B, Line 12c CONFLICT OF INTEREST POLICY COMPLIANCE: EACH DIRECTOR, PRIOR TO MAKING THE POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT ANNUALLY IN WRITING TO THE BOARD OF DIRECTORS A LIST OF ALL BUSINESSES OR OTHER ENTITIES OF WHICH HE OR SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE ORGANIZATION HAS, OR MIGHT REASONABLELY IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST. Form 990, Part VI, Section B, Line 15 CURRENTLY ALL OFFICERS OF THE ORGANIZATION, INCLUDING CEO, TREASURER, AND SECRETARY, ARE PROVIDING PRO BONO SERVICE TO THE ORGANIZATION. IN THE FUTURE WHEN THE ORGANIZATION IS FINANCIALLY CAPABLE, THE BOARD OF DIRECTORS, ON AN ANNUAL BASIS, WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION FOR OFFICERS. THE PROCESS INCLUDES ALL OF THE FOLLOWING THREE ELEMENTS: (1) REVIEW AND APPROVAL BY THE BOARD OF DIRECTORS, BASED ON PERFORMANCE AND RESPONSIBILITIES; (2) REVIEW OF "COMPARABLE COMPENSATION" DATA OF THE PEER ORGANIZATIONS; (3) DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION AGREEMENT, ARE KEPT BY THE SECRETARY OF THE ORGANIZAITON. Form 990, Part VI, Section C, Line 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST AT INFO@AIM-HIACCELERATOR.ORG